Mirum Pharmaceuticals Inc (MIRM) Noticias

Form 4 - Statement of changes in beneficial ownership of securities

Les données à long terme des études LIVMARLI de Mirum sur l’ALGS et la PFIC présentées au congrès de l’EASL

- Les données montrent un bénéfice clinique soutenu après sept ans de traitement par LIVMARLI chez les patients atteints du syndrome d’Alagille...

Form 8-K - Current report

Long-Term Data from Mirum’s LIVMARLI Studies in ALGS and PFIC Highlighted at EASL Congress

- Data showcases sustained clinical benefit following seven years of LIVMARLI treatment in patients with Alagille syndrome - Long-term extension...

Mirum Pharmaceuticals to Present at the Goldman Sachs 45th Annual Global Healthcare Conference

Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a biopharmaceutical company focused on the identification, acquisition, development and...

Mirum Pharmaceuticals: positive CHMP-Stellungnahme für LIVMARLI® (Maralixibat) als orale Lösung zur Behandlung von PFIC bei Patienten ab einem Alter von drei Monaten

Positive CHMP-Stellungnahme auf der Grundlage der Phase-3-Studie MARCH mit statistisch hochsignifikanter (p<0,0001) Verringerung des...

Mirum Pharmaceuticals annonce un avis favorable du CHMP pour la solution orale LIVMARLI® (maralixibat) dans le traitement des patients atteints de CIFP âgés de trois mois et plus

Avis favorable du CHMP basé sur l’étude MARCH de phase 3 avec une réduction hautement statistiquement pertinente (p<0,0001) de la sévérité du...

Mirum Pharmaceuticals Announces Positive CHMP Opinion for LIVMARLI® (maralixibat) Oral Solution for the Treatment of PFIC in Patients Three Months of Age and Older

Positive opinion from CHMP based on Phase 3 MARCH study with highly statistically significant (p<0.0001) reduction in pruritus severity...

Long-Term Data from Mirum’s LIVMARLI Studies in ALGS and PFIC to be Presented at EASL Congress

- Data showcases sustained clinical benefit following 7 years of LIVMARLI treatment in patients with Alagille syndrome - Long-term extension data...

Mirum Pharmaceuticals’ LIVMARLI Data Showcased at ESPGHAN Annual Meeting

- Seven abstracts highlighting ALGS and PFIC data, including three oral presentations - Long-term extension data from Phase 3 MARCH-ON PFIC study...

Form 4 - Statement of changes in beneficial ownership of securities

Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced that on May 10, 2024, the Compensation Committee of Mirum’s Board of Directors granted...

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report